Picture EBD Group BIO-Europe 2021 Digital BEU2021 650x80
Document › Details

Oxford Biomedica plc. (2/7/19). "Press Release: Oxford Biomedica Provides Update on Programmes Outlicensed to Sanofi". Oxford.

Organisations Organisation Oxford Biomedica plc (LSE: OXB)
  Group Oxford Biomedica (Group)
  Organisation 2 Sanofi S.A. (Euronext: SAN, Nasdaq: SNY)
  Group Sanofi (Group) [since May 2011]
Products Product gene therapy
  Product 2 ophthalmic
Index terms Index term Sanofi–Oxford BioMedica: ophthalmic gene therapy, 2009–201902c collab developm + commerc Sanofi SEEKS NEW PARTNERS 2/19
  Index term 2 Bioverativ–Oxford BioMedica: lentiviral vectors, 201802– collab $5m upfront + >$100m milestones developm + manufacturing vectors for haemophilia
Persons Person Dawson, John (Oxford BioMedica 200810– CEO before Cephalon Europe)
  Person 2 Neal, Matthew (Consilium Strategic Communications 201602)

Oxford Biomedica plc (LSE: OXB), (“OXB” or “the Group”), a leading gene and cell therapy group, has been informed that as part of a company-wide portfolio review, Sanofi intends to seek a new partner for OXB’s outlicensed ophthalmology gene therapies, SAR422459 for Stargardt disease and SAR421869 for Usher’s Syndrome type 1b.

Sanofi has confirmed that it will continue with its ongoing Phase I/II proof-of-concept study with SAR422459, while it will not continue to develop SAR421869. Sanofi is currently in discussions with potential external partners to continue the further development of both of these programmes.

SAR422459 and SAR421869 relate to a development and commercialisation licence agreement signed with Sanofi in 2009. The portfolio review has no short or medium term material financial impact on the Group.

OXB’s collaboration and licence agreement with Bioverativ (a Sanofi company), for the development and manufacturing of lentiviral vectors to treat haemophilia, remains unaffected by the portfolio review.

John Dawson, Chief Executive Officer of Oxford Biomedica, said:
“We remain supportive of Sanofi’s ongoing efforts to ensure the future development of SAR422459 and SAR421869. These important gene therapy programmes have the potential to provide one-time treatments for two ophthalmology indications with unmet medical needs and we are ready to support their transition to a new partner.”

For further information, please contact:

Oxford Biomedica plc
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Catherine Isted, Head of Corporate Development and IR
Sarah MacLeod, Head of Communications

Tel: +44 (0)1865 783 000
Tel: +44 (0)1865 954 161

Financial and corporate communications enquiries:

Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal
Tel: +44 (0)20 3709 5700


About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations and GC LabCell, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 360 people. Further information is available at

Record changed: 2020-06-08


Picture [iito] Plain Stupid Simple 650x80px

More documents for Oxford Biomedica (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group BIO-Europe 2021 Time to Register 650x300

» top